The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesMicroRNA fingerprints during human megakaryocytopoiesisPrognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyMicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemiaIdentification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemiaThe prognostic and functional role of microRNAs in acute myeloid leukemiaFLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyFavorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaRUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Molecular classification of cancer: class discovery and class prediction by gene expression monitoringThe World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)All-trans-retinoic acid in acute promyelocytic leukemiaChromosome 12 breakpoints are cytogenetically different in benign and malignant lipogenic tumors: localization of breakpoints in lipoma to 12q15 and in myxoid liposarcoma to 12q13.3Acute Myeloid LeukemiaMolecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogeneticsClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewGenome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.Significance of haematological parameters in the non-Hodgkin's malignant lymphomas.Controversies in transfusion medicine. Prophylactic platelet transfusion therapy: pro.Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Interferon therapy of relapsed and refractory Hodgkin's disease: Cancer and Leukemia Group B Study 8652.Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902.Combination trial of subcutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology, non-Hodgkin's lymphoma.Acute nonlymphocytic leukemia in patients with nodular lymphoma.Effect of age on therapeutic response and survival in advanced Hodgkin's disease.Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts.A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia
P50
Q22299206-B7767D57-ACF6-4CFE-872B-F3B2DCB6F30DQ24546361-762F3837-5B56-44DE-9915-20035A06E298Q24643738-2272559C-2648-4361-8EE5-F36BD0CC82DAQ24655915-BE2DFA9E-3652-480E-8F48-9F90CAD96B9EQ24670279-0E58D0A6-3244-4559-8327-CED1B19C3EADQ27693865-9E08322D-3D35-4016-8905-2E34D3BD4803Q27851415-79CD3CF5-59F2-4BCB-AED1-41ECD38FD153Q27851436-AE9A08FC-72B4-4DA7-B309-C11F30CE571FQ27851545-D232AD35-AF62-4459-9C0F-7C270B4563D8Q27851621-592767DF-6944-468D-A9DE-4D98F0DB4C6AQ27851679-4BC6BBEB-AEF5-4ADA-8BB3-97F1B1D7086EQ27851689-8063C922-2576-401F-A633-FDCEA86A3CC3Q27851713-B89D5452-CFD9-4A0C-A779-57F9291A6810Q27851839-95C74E16-D8DC-40B6-8813-B4321680183AQ27853375-3298975B-E1E0-4654-B518-60E92C18AE2AQ27861072-852141BE-E0CB-43F1-A863-3C5F75C63AECQ28142473-BD9F8C2F-576B-4110-80DE-773B0BFBD697Q28143029-C37A6890-F18D-4275-8D98-DC29DE9FC976Q28209814-8D8EE288-FCE0-47EA-BE17-A103ECFD3D99Q28250406-38CE1612-889D-4137-9EAE-491113690F20Q28267219-000FF533-F124-443B-B189-4E89BB95485DQ28267442-C7FB69FE-A6C8-4834-A49C-AA5373FEADDCQ28298765-9C9E6CE8-46AB-4327-87BB-1B93DAAFD85CQ28301344-F99FEA4B-08D6-4FA3-873C-5CF3D3575821Q30449092-B07899AA-6FA7-420A-A104-4FD593555262Q33339274-474F7E7D-1416-4C13-9B50-B93683F49402Q33344274-84AFD765-E2D9-4129-A830-2D78D472F234Q33346645-147E8842-B49B-44BA-904A-3C7561480A33Q33365998-B631E02E-AD50-4D85-8B8C-3A3E177173A2Q33380148-DB7B5132-C53B-4BE5-8616-7E98463F6089Q33393647-50619B02-DCBE-4439-9AD4-18D8A2088DF4Q33404610-EF645C36-C7E3-4C8B-B84C-6A20E2443F6DQ33449195-7986872B-58D2-4821-9AE4-13C77093D476Q33449722-251EC40F-3567-401C-97D0-ACDCB51BFA08Q33473743-7E627AD6-4FFA-4476-9F3C-6BAF6B55FD21Q33483937-E262387D-04A9-4766-AF28-006811575DADQ33503387-723922BC-2D6F-46C3-96AC-0AB23995179FQ33503445-34AAAFDF-1CEB-4AA6-8025-5819F996BB40Q33558183-05CFB586-08C4-4EBC-85B9-A5E7F17F4314Q33623126-0997DDB8-0169-4E01-B06C-AE97A8D953DD
P50
description
Ameerika Ühendriikide arst
@et
American physician
@en
Amerikaans arts
@nl
dochtúir Meiriceánach
@ga
doctoriță americană
@ro
dokter asal Amerika Serikat
@id
mediciste american
@lfn
metgessa estatunidenca
@ca
mjeke amerikane
@sq
médecin américaine
@fr
name
Clara D. Bloomfield
@ast
Clara D. Bloomfield
@ca
Clara D. Bloomfield
@da
Clara D. Bloomfield
@de
Clara D. Bloomfield
@en
Clara D. Bloomfield
@es
Clara D. Bloomfield
@fr
Clara D. Bloomfield
@ga
Clara D. Bloomfield
@nb
Clara D. Bloomfield
@nl
type
label
Clara D. Bloomfield
@ast
Clara D. Bloomfield
@ca
Clara D. Bloomfield
@da
Clara D. Bloomfield
@de
Clara D. Bloomfield
@en
Clara D. Bloomfield
@es
Clara D. Bloomfield
@fr
Clara D. Bloomfield
@ga
Clara D. Bloomfield
@nb
Clara D. Bloomfield
@nl
altLabel
Bloomfield C
@en
Bloomfield C. D.
@en
Bloomfield C.
@en
Bloomfield CD
@en
Bloomfield
@en
C Bloomfield
@en
C D Bloomfield
@en
C. Bloomfield
@en
C. D. Bloomfield
@en
Clara Bloomfield
@en
prefLabel
Clara D. Bloomfield
@ast
Clara D. Bloomfield
@ca
Clara D. Bloomfield
@da
Clara D. Bloomfield
@de
Clara D. Bloomfield
@en
Clara D. Bloomfield
@es
Clara D. Bloomfield
@fr
Clara D. Bloomfield
@ga
Clara D. Bloomfield
@nb
Clara D. Bloomfield
@nl
P166
P1006
P214
P2163
P244
P1006
P106
P1412
P1559
Clara D. Bloomfield
@en
P166
P19
P20
P21
P214
P2163
P244
P31
P569
1942-05-15T00:00:00Z
P570
2020-03-01T00:00:00Z